RegeneMed is a privately held company incorporated in the State of California in 2003. The company was founded
by the Co-Founder of Advanced Tissue Sciences (ATS) and the Lead Scale-up Engineer for ATS. Current funding
is from Angel Investors, Pharmaceutical Research Collaborations and
National Institute of Health (NIH) Small Business Innovative Research
(SBIR) grants.

RegeneMed launched its first product,
RegeneTOX, human and animal
3-D liver tissue co-cultures, for use in pharmaceutical drug
discovery in June, 2007.

A financing round to fund scale-up of the liver product and expansion
to new cell and tissue types for application to drug discovery, medical
devices and transplantation is expected in 2008.
If you are interested in investment opportunities, please
(password protected)